Transcriptomics

Dataset Information

298

Gene expression profiling of neuroendocrine primary tumors: effect of Octreotide treatment


ABSTRACT: Gene expression profiles of primary neuroendocrine tumors treated or not with 1µM Octreotide.We investigated 5 human neuroendocrine cell lines, CNDT2.5 and KRJ1, established from ileum NETs, QGP1 by a pancreatic NET, NCI H720 and NCI H727 from bronchopulmonary NETs. CNDT2.5 cell wereconstantly treated with 1µM octreotide for 10 and 16 months. We isolated total RNA (Ambion, PARIS Kit) from 5 WT cell lines and CNDT2.5 treated with octreotide (Santostatin, Novartis). Total RNA was hybridized onto the Affymetrix Human Gene 1.0 ST Array by Affymetrix Uppsala Platform, UU. SE (Uppsala, Sweden). We first wanted to verify whether the different cell lines may become reliable models to study neuroendocrine signaling pathways. The main objective of this project aimed at understanding the mechanisms by which octreotide (Sandostatin, Novartis) alter cellular growth and differentiation of CNDT2.5 cells. We therefore focused on intermediate (10 months) and long stimulation (16 months) events triggered by sandostatin, which lead variation of CNDT.2.5 cells gene expression to identify potential pivotal genes involved in the development of drug resistance in neuroendocrine cells.

ORGANISM(S): Homo sapiens  

SUBMITTER: Jean-Baptiste Demoulin  

PROVIDER: E-MTAB-388 | ArrayExpress | 2013-01-08

REPOSITORIES: ArrayExpress

altmetric image

Publications

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.

Li Su-Chen SC   Martijn Cécile C   Cui Tao T   Essaghir Ahmed A   Luque Raúl M RM   Demoulin Jean-Baptiste JB   Castaño Justo P JP   Öberg Kjell K   Giandomenico Valeria V  

PloS one 20121031 10


Octreotide is a widely used synthetic somatostatin analogue that significantly improves the management of neuroendocrine tumours (NETs). Octreotide acts through somatostatin receptors (SSTRs). However, the molecular mechanisms leading to successful disease control or symptom management, especially when SSTRs levels are low, are largely unknown. We provide novel insights into how octreotide controls NET cells. CNDT2.5 cells were treated from 1 day up to 16 months with octreotide and then were pro  ...[more]

Similar Datasets

2012-12-12 | E-GEOD-24358 | ArrayExpress
| GSE24358 | GEO
2013-03-01 | E-GEOD-33568 | ArrayExpress
2012-11-08 | E-MTAB-862 | ArrayExpress
2008-06-14 | E-GEOD-5910 | ArrayExpress
| GSE65286 | GEO
2015-02-16 | E-MTAB-2980 | ArrayExpress
2013-12-31 | E-GEOD-43795 | ArrayExpress
| GSE98546 | GEO
| PRJNA132815 | ENA